Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Inclusion Body Myositis: early-phase trial registry

3 of 11 indexed Inclusion Body Myositis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Inclusion Body Myositis: 11 US clinical trials tracked, 3 recruiting.

Inclusion Body Myositis is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Kansas Medical Center, running 3 of these trials.

Enrollment posture brief

Registry condition inclusion-body-myositis

OPEN 3 | RECR 27% | LATE 1 | EARLY 2 | RANK #1577 | SPON 3

Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Inclusion Body Myositis (thi…27%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Inclusion Body Myositis

Inclusion Body Myositis lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Inclusion Body Myositis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Inclusion Body Myositis is recruiting below its size-band peers.

    3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Inclusion Body Myositis research.

    University of Kansas Medical Center accounts for 3 of 11 trials (27.3%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Inclusion Body Myositis trials plan to enrol fewer than 100 people.

    Median target enrolment is 31 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.

  4. Inclusion Body Myositis splits between interventional and observational designs.

    5 interventional and 6 observational studies make up this index (45.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 31

Open and recent trials

11 total, page 1 of 1

RECRUITING 1,200 participants

Adult and Juvenile Myositis

National Institute of Environmental Health Sciences (NIEHS)

NCT00017914

RECRUITING 700 participants

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

Myositis International Health & Research Collaborative Alliance Foundation

NCT07374107

RECRUITING NA 50 participants

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

University of Missouri-Columbia

NCT07478172

ACTIVE NOT RECRUITING 150 participants

Sporadic Inclusion Body Myositis Natural History Study

University of California, Irvine

NCT05046821

ACTIVE NOT RECRUITING Phase 3 140 participants

Phase III Trial of Sirolimus in IBM

University of Kansas Medical Center

NCT04789070

ACTIVE NOT RECRUITING 20 participants

Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time

University of Kansas Medical Center

NCT06153108

COMPLETED 31 participants

Establishing Muscle Impedance Parameters With Electrical Impedance Myography

Yale University

NCT03633318

COMPLETED 20 participants

Lithium in Inclusion Body Myositis (IBM)

Phoenix Neurological Associates

NCT00917956

COMPLETED Early Phase 1 20 participants

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis

Washington University School of Medicine

NCT00802815

COMPLETED Phase 1 19 participants

Study of Pioglitazone in Sporadic Inclusion Body Myositis

Johns Hopkins University

NCT03440034

COMPLETED NA 9 participants

Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells

University of Kansas Medical Center

NCT04975841

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 3 1

Named interventions

Most-linked intervention names on Inclusion Body Myositis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

electrical impedance myography (EIM) Device
1 trials
Etanercept Drug
1 trials
PAMSys pendant PAMSys wrist sensors Device
1 trials
Adipose Derived Regenerative Cells Device
1 trials
No intervention - qualitative and mixed methods investigations Other
1 trials
Whole-body Electrical Muscle Stimulation Exercise Device
1 trials
Pioglitazone Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Inclusion Body Myositis trials. A trial with sites in several states counts in each.

Maryland 4 trials
Kansas 4 trials
Missouri 3 trials
Washington 2 trials
Texas 2 trials
Pennsylvania 1 trials
Oregon 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Inclusion Body Myositis page

11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Inclusion Body Myositis condition card totals 11 registered trials; most-linked intervention electrical impedance myography (EIM); top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.